Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin

A. Bacigalupo, M. T. Van Lint, R. Cerri

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.

Original languageEnglish
Pages (from-to)168-171
Number of pages4
JournalBlut
Volume41
Issue number3
Publication statusPublished - 1980

Fingerprint

Aplastic Anemia
Globulins
Methylprednisolone
Therapeutics
Interstitial Lung Diseases
Prednisolone
Immunosuppression
Sepsis
Bone Marrow
Maintenance
Hemorrhage
Transplants
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin. / Bacigalupo, A.; Van Lint, M. T.; Cerri, R.

In: Blut, Vol. 41, No. 3, 1980, p. 168-171.

Research output: Contribution to journalArticle

@article{4124b1fffe19454c88d79ea11f3755d7,
title = "Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin",
abstract = "Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41{\%}) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76{\%}). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83{\%} at 2 yr.",
author = "A. Bacigalupo and {Van Lint}, {M. T.} and R. Cerri",
year = "1980",
language = "English",
volume = "41",
pages = "168--171",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Treatment of severe aplastic anemia with bolus 6-methylprednisolone and antilymphocytic globulin

AU - Bacigalupo, A.

AU - Van Lint, M. T.

AU - Cerri, R.

PY - 1980

Y1 - 1980

N2 - Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.

AB - Twenty two patients with severe aplastic anemia (SAA) received bolus 6-methylprednisolone (B/6-MPr) on admission. All patients received at least 100 mg/kg of B/6-MPr intravenously on the first week of treatment. Nine patients (41%) achieved a complete autologous hematologic reconstitution and are alive and well between 118 and 760 days posttreatment. Thirteen patients were refractory: 8 of these received ALG, 3 were transplanted and 2 are being evaluated. Of the 8 patients who received ALG, 4 entered a complete autologous reconstitution and are alive and well between 420 and 735 days from therapy; 1 is alive but is still aplastic 200 days from initial treatment, and 3 died (2 of acute hemorrhage following ALG and 1 of sepsis and marrow failure on day 80). Of the 3 patients grafted 2 are complete chimeras 170 and 732 days post-transplant and 1 died of interstitial pneumonitis on day 72. The overall complete response rate to B/6-MPr and ALG was of 13 out of 17 evaluable patients (76%). Eleven have been taken off maintenance prednisolone. The overall survival of 19 patients given immunosuppression only (with the exclusion of the 3 transplanted cases) is 83% at 2 yr.

UR - http://www.scopus.com/inward/record.url?scp=0018934529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018934529&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018934529

VL - 41

SP - 168

EP - 171

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -